EMS Group inaugurates NovaMed/EMS, Manaus' first pharmaceutical factory
Brazilian Minister of Health Arthur Chioro participated in the inauguration ceremony of NovaMed/EMS, the first pharmaceutical factory opened in Brazil’s city of Manaus (Amazonas state) this week. Manaus' Free Zone is located in the North region of the country, writes Juliane Carvalho on Brazil Pharma News.
The construction of the manufacturing plant, which is part of the Brazilian pharmaceutical group EMS, received 260 million real ($114 million) in funds from the BNDES (Brazil's National Bank) Support Program of the Health Industrial Complex Development (BNDES Profarma). The total construction investment was 385 million real. The new production facility is expected to produce about 1.5 billion generic tablets per month.
The factory is part of the promotion of the development of health policy in Brazil managed by the Ministry of Health. Through this policy, the federal government attracts and promotes investments to the country, in addition to expanding the production capacity of all types of medications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze